Agreement rates among single photon emission computed tomography using gallium-67, computed axial tomography and lymphangiography for Hodgkin disease and correlation of image findings with clinical outcome

Chul S. Ha, Jae-Gol Choe, Joseph S. Kong, Pamela K. Allen, Yoon K. Oh, James D. Cox, E. Edmundkim

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

BACKGROUND. This study was undertaken to systematically evaluate the agreement rates among single photon emission computed tomography using gallium-67 (Ga-67 SPECT), lymphangiography (LAG), and computed axial tomography (CT) scan findings for Hodgkin disease and to correlate radiologic findings with clinical outcome. METHODS. One hundred three previously untreated patients with Hodgkin disease who had Ga-67 SPECT scan between August 1992 and December 1994 at our institution form the basis of this study. The agreement rates among Ga-67 SPECT, LAG, and CT scan findings were calculated by sites from the pretreatment evaluation throughout the courses of chemotherapy. The probabilities of recurrence or progression by sites were correlated with the radiologic findings. RESULTS. The median follow-up was 3 years. The pretreatment agreement ranged from 75% to 100% between Ga-67 SPECT and CT scans, 85-100% between CT scan and LAG, and 74-99% between Ga-67 SPECT and LAG. A greater variation in agreement was observed once chemotherapy was started, the site with the least agreement being the mediastinum. The most common site of the recurrence or progression was also the mediastinum. When the CT scan showed persistent abnormality even after Ga-67 SPECT turned negative after chemotherapy, the chances of mediastinal recurrence or progression were 3 in 34 and 3 in 18 after 1-3 cycles and 4-6 cycles, respectively. CONCLUSIONS. Although there was a relatively high correlation between Ga-67 SPECT and the other modalities, the intrinsic limitation of planar Ga-67 was still observed in Ga-67 SPECT especially in the mediastinum. There was still a moderate risk of mediastinal recurrence or progression even after residual CT scan abnormality lost gallium avidity from chemotherapy. (C) 2000 American Cancer Society.

Original languageEnglish
Pages (from-to)1371-1379
Number of pages9
JournalCancer
Volume89
Issue number6
DOIs
Publication statusPublished - 2000 Sep 15
Externally publishedYes

Fingerprint

Lymphography
Gallium
Single-Photon Emission-Computed Tomography
Hodgkin Disease
Tomography
Mediastinum
Recurrence
Drug Therapy

Keywords

  • Computed axial tomography
  • Gallium
  • Lymphangiography
  • Single photon emission computed tomography (SPECT)

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Agreement rates among single photon emission computed tomography using gallium-67, computed axial tomography and lymphangiography for Hodgkin disease and correlation of image findings with clinical outcome. / Ha, Chul S.; Choe, Jae-Gol; Kong, Joseph S.; Allen, Pamela K.; Oh, Yoon K.; Cox, James D.; Edmundkim, E.

In: Cancer, Vol. 89, No. 6, 15.09.2000, p. 1371-1379.

Research output: Contribution to journalArticle

@article{5cdddd49c6c34e4bb5c73510a1d142b5,
title = "Agreement rates among single photon emission computed tomography using gallium-67, computed axial tomography and lymphangiography for Hodgkin disease and correlation of image findings with clinical outcome",
abstract = "BACKGROUND. This study was undertaken to systematically evaluate the agreement rates among single photon emission computed tomography using gallium-67 (Ga-67 SPECT), lymphangiography (LAG), and computed axial tomography (CT) scan findings for Hodgkin disease and to correlate radiologic findings with clinical outcome. METHODS. One hundred three previously untreated patients with Hodgkin disease who had Ga-67 SPECT scan between August 1992 and December 1994 at our institution form the basis of this study. The agreement rates among Ga-67 SPECT, LAG, and CT scan findings were calculated by sites from the pretreatment evaluation throughout the courses of chemotherapy. The probabilities of recurrence or progression by sites were correlated with the radiologic findings. RESULTS. The median follow-up was 3 years. The pretreatment agreement ranged from 75{\%} to 100{\%} between Ga-67 SPECT and CT scans, 85-100{\%} between CT scan and LAG, and 74-99{\%} between Ga-67 SPECT and LAG. A greater variation in agreement was observed once chemotherapy was started, the site with the least agreement being the mediastinum. The most common site of the recurrence or progression was also the mediastinum. When the CT scan showed persistent abnormality even after Ga-67 SPECT turned negative after chemotherapy, the chances of mediastinal recurrence or progression were 3 in 34 and 3 in 18 after 1-3 cycles and 4-6 cycles, respectively. CONCLUSIONS. Although there was a relatively high correlation between Ga-67 SPECT and the other modalities, the intrinsic limitation of planar Ga-67 was still observed in Ga-67 SPECT especially in the mediastinum. There was still a moderate risk of mediastinal recurrence or progression even after residual CT scan abnormality lost gallium avidity from chemotherapy. (C) 2000 American Cancer Society.",
keywords = "Computed axial tomography, Gallium, Lymphangiography, Single photon emission computed tomography (SPECT)",
author = "Ha, {Chul S.} and Jae-Gol Choe and Kong, {Joseph S.} and Allen, {Pamela K.} and Oh, {Yoon K.} and Cox, {James D.} and E. Edmundkim",
year = "2000",
month = "9",
day = "15",
doi = "10.1002/1097-0142(20000915)89:6<1371::AID-CNCR22>3.0.CO;2-S",
language = "English",
volume = "89",
pages = "1371--1379",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Agreement rates among single photon emission computed tomography using gallium-67, computed axial tomography and lymphangiography for Hodgkin disease and correlation of image findings with clinical outcome

AU - Ha, Chul S.

AU - Choe, Jae-Gol

AU - Kong, Joseph S.

AU - Allen, Pamela K.

AU - Oh, Yoon K.

AU - Cox, James D.

AU - Edmundkim, E.

PY - 2000/9/15

Y1 - 2000/9/15

N2 - BACKGROUND. This study was undertaken to systematically evaluate the agreement rates among single photon emission computed tomography using gallium-67 (Ga-67 SPECT), lymphangiography (LAG), and computed axial tomography (CT) scan findings for Hodgkin disease and to correlate radiologic findings with clinical outcome. METHODS. One hundred three previously untreated patients with Hodgkin disease who had Ga-67 SPECT scan between August 1992 and December 1994 at our institution form the basis of this study. The agreement rates among Ga-67 SPECT, LAG, and CT scan findings were calculated by sites from the pretreatment evaluation throughout the courses of chemotherapy. The probabilities of recurrence or progression by sites were correlated with the radiologic findings. RESULTS. The median follow-up was 3 years. The pretreatment agreement ranged from 75% to 100% between Ga-67 SPECT and CT scans, 85-100% between CT scan and LAG, and 74-99% between Ga-67 SPECT and LAG. A greater variation in agreement was observed once chemotherapy was started, the site with the least agreement being the mediastinum. The most common site of the recurrence or progression was also the mediastinum. When the CT scan showed persistent abnormality even after Ga-67 SPECT turned negative after chemotherapy, the chances of mediastinal recurrence or progression were 3 in 34 and 3 in 18 after 1-3 cycles and 4-6 cycles, respectively. CONCLUSIONS. Although there was a relatively high correlation between Ga-67 SPECT and the other modalities, the intrinsic limitation of planar Ga-67 was still observed in Ga-67 SPECT especially in the mediastinum. There was still a moderate risk of mediastinal recurrence or progression even after residual CT scan abnormality lost gallium avidity from chemotherapy. (C) 2000 American Cancer Society.

AB - BACKGROUND. This study was undertaken to systematically evaluate the agreement rates among single photon emission computed tomography using gallium-67 (Ga-67 SPECT), lymphangiography (LAG), and computed axial tomography (CT) scan findings for Hodgkin disease and to correlate radiologic findings with clinical outcome. METHODS. One hundred three previously untreated patients with Hodgkin disease who had Ga-67 SPECT scan between August 1992 and December 1994 at our institution form the basis of this study. The agreement rates among Ga-67 SPECT, LAG, and CT scan findings were calculated by sites from the pretreatment evaluation throughout the courses of chemotherapy. The probabilities of recurrence or progression by sites were correlated with the radiologic findings. RESULTS. The median follow-up was 3 years. The pretreatment agreement ranged from 75% to 100% between Ga-67 SPECT and CT scans, 85-100% between CT scan and LAG, and 74-99% between Ga-67 SPECT and LAG. A greater variation in agreement was observed once chemotherapy was started, the site with the least agreement being the mediastinum. The most common site of the recurrence or progression was also the mediastinum. When the CT scan showed persistent abnormality even after Ga-67 SPECT turned negative after chemotherapy, the chances of mediastinal recurrence or progression were 3 in 34 and 3 in 18 after 1-3 cycles and 4-6 cycles, respectively. CONCLUSIONS. Although there was a relatively high correlation between Ga-67 SPECT and the other modalities, the intrinsic limitation of planar Ga-67 was still observed in Ga-67 SPECT especially in the mediastinum. There was still a moderate risk of mediastinal recurrence or progression even after residual CT scan abnormality lost gallium avidity from chemotherapy. (C) 2000 American Cancer Society.

KW - Computed axial tomography

KW - Gallium

KW - Lymphangiography

KW - Single photon emission computed tomography (SPECT)

UR - http://www.scopus.com/inward/record.url?scp=0034666252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034666252&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(20000915)89:6<1371::AID-CNCR22>3.0.CO;2-S

DO - 10.1002/1097-0142(20000915)89:6<1371::AID-CNCR22>3.0.CO;2-S

M3 - Article

VL - 89

SP - 1371

EP - 1379

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -